HealthCare Global Enterprises (HCG) has teamed up with Accenture to propel advancements in cancer research and treatment by harnessing the power of cutting-edge artificial intelligence (AI), including generative AI and deep learning for multi-dimensional, patient-specific data analysis.
This alliance merges Accenture’s worldwide acumen in data and AI, covering AI/machine learning (ML), generative AI, and quantum computing, with HCG’s substantial clinical knowledge in oncology. This synergy aims to facilitate the early diagnosis and management of a variety of cancers.
As a component of this joint venture, Accenture will apply advanced technologies, such as image analysis software, informatics, and innovative algorithms, to scrutinize cancer patient data and assess molecular variations that can significantly influence patient care. As the first initiative of its nature in South Asia, the program will utilize Accenture’s generative AI studios to inspire groundbreaking research for the discovery and advancement of new pharmaceutical targets, processes, pathways, and biomarkers associated with diverse cancer types.
Moreover, the program strives to deepen the comprehension of different cancers by exploring their growth, symptoms, and roots, paving the way for novel treatment algorithms to refine precision medicine and enhance the quality of therapy and care. Through the application of AI, generative AI, cloud computing, machine learning, and quantum computing, it aims to exhibit data-driven clinical practices and streamline patient care efficiency. Initially concentrating on detecting molecular patterns for prognosis and treatment reactions for lung adenocarcinoma and head and neck cancers, the research will gradually extend to other cancer varieties.
Dr. B S Ajaikumar, Executive Chairman, HealthCare Global Enterprises Limited, expressed, “In today’s context, refining cancer care demands tech-enhanced progress in research and education, crucial for executing seamless, accurate data collection and transmission. Considering the heterogeneity of tumor genetics and various omics, AI has become vital for precise, personalized medical progress. AI-inspired innovations have re-evaluated existing drugs for certain tumors, which was unforeseen earlier. Accenture’s expertise in technology and analytics, utilizing AI modeling, will significantly bolster our research endeavors directed towards creating patient-focused therapies with enduring effects. This cooperative initiative is an integral element of our internal research efforts, epitomizing our leadership in cancer care driven by groundbreaking innovation.”
Senthil Ramani, Global Lead of Data and AI at Accenture, stated, “Innovative computing technologies, such as generative AI, alongside comprehensive biological and clinical knowledge, hold transformative potential in cancer research and care, meeting patient needs and supporting the global healthcare system broadly. Together with HCG, we are blending our global data and AI expertise with life sciences research and development to remarkably and swiftly enhance decision-making for cancer patient treatment and care in South Asia, and globally.”